the five suitors of srx

The five possible suitors circling around the high growth SRX are Cephalon., Roche, Sanofi, Genentech and Pfizer. All five have in common lower margin businesses versus very high SRX 80% gross margin business. All also have complementary chemotherapy drugs that work well in extending survival times by over 100% in many cases with the use of Sirtex Sir Spheres. AT 10x eps with growth between 70-100%, SRX wont be this low for very long. The PEG ratio of 10/70=.14 is the lowest of biotechs, as most biotechs sell at PEG ratios of 1-2. I am adding more shares as I did 2 weeks ago.My little opinion only after being in industry for over 30 yrs.Do your own work